These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 27151349)

  • 1. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.
    Sayed N; Liu C; Wu JC
    J Am Coll Cardiol; 2016 May; 67(18):2161-2176. PubMed ID: 27151349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced pluripotent stem cells and their implication for regenerative medicine.
    Csobonyeiova M; Polak S; Koller J; Danisovic L
    Cell Tissue Bank; 2015 Jun; 16(2):171-80. PubMed ID: 25037593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association.
    Musunuru K; Sheikh F; Gupta RM; Houser SR; Maher KO; Milan DJ; Terzic A; Wu JC;
    Circ Genom Precis Med; 2018 Jan; 11(1):e000043. PubMed ID: 29874173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cells (iPSCs) derived from different cell sources and their potential for regenerative and personalized medicine.
    Shtrichman R; Germanguz I; Itskovitz-Eldor J
    Curr Mol Med; 2013 Jun; 13(5):792-805. PubMed ID: 23642060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new era of disease modeling and drug discovery using induced pluripotent stem cells.
    Suh W
    Arch Pharm Res; 2017 Jan; 40(1):1-12. PubMed ID: 27921262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Human-induced Pluripotent Stem Cell the Best Optimal?
    Wang F; Kong J; Cui YY; Liu P; Wen JY
    Chin Med J (Engl); 2018 Apr; 131(7):852-856. PubMed ID: 29578130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced Pluripotent Stem Cells (iPSCs) in Developmental Toxicology.
    Easley CA
    Methods Mol Biol; 2019; 1965():19-34. PubMed ID: 31069666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.
    Tzatzalos E; Abilez OJ; Shukla P; Wu JC
    Adv Drug Deliv Rev; 2016 Jan; 96():234-244. PubMed ID: 26428619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing.
    Yin X; Li Q; Shu Y; Wang H; Thomas B; Maxwell JT; Zhang Y
    J Biomed Sci; 2024 May; 31(1):47. PubMed ID: 38724973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced pluripotency for translational research.
    Wu M; Chen G; Hu B
    Genomics Proteomics Bioinformatics; 2013 Oct; 11(5):288-93. PubMed ID: 24056061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery.
    Nsair A; MacLellan WR
    Adv Drug Deliv Rev; 2011 Apr; 63(4-5):324-30. PubMed ID: 21371511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.
    Campbell KA; Terzic A; Nelson TJ
    Regen Med; 2015; 10(6):773-83. PubMed ID: 26439809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comment on pluripotent stem cells in next-generation biomedical theranostics.
    Rossbach M
    Curr Mol Med; 2013 Jun; 13(5):879-83. PubMed ID: 23642068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Regenerative Medicine.
    Arjmand B; Goodarzi P; Mohamadi-Jahani F; Falahzadeh K; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):144-149. PubMed ID: 28282715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
    Murata M; Tohyama S; Fukuda K
    Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem cells in regenerative medicine and disease modeling.
    Walmsley GG; Hyun J; McArdle A; Senarath-Yapa K; Hu MS; Chung MT; Wong VW; Longaker MT; Wan DC
    Curr Stem Cell Res Ther; 2014 Mar; 9(2):73-81. PubMed ID: 24359141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived induced pluripotent stem cells in cancer research and precision oncology.
    Papapetrou EP
    Nat Med; 2016 Dec; 22(12):1392-1401. PubMed ID: 27923030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
    Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
    Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome Editing and Induced Pluripotent Stem Cell Technologies for Personalized Study of Cardiovascular Diseases.
    Chun YW; Durbin MD; Hong CC
    Curr Cardiol Rep; 2018 Apr; 20(6):38. PubMed ID: 29666931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human induced pluripotent stem cells: A disruptive innovation.
    De Vos J; Bouckenheimer J; Sansac C; Lemaître JM; Assou S
    Curr Res Transl Med; 2016; 64(2):91-6. PubMed ID: 27316392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.